{"id":"glimepiride-hoe490","safety":{"commonSideEffects":[{"rate":"5–15","effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Gastrointestinal disturbances"}]},"_chembl":{"chemblId":"CHEMBL1481","moleculeType":"Small molecule","molecularWeight":"490.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glimepiride is a meglitinide-class sulfonylurea that closes ATP-sensitive potassium channels in pancreatic beta cells, leading to cell depolarization and calcium influx, which triggers insulin release. This mechanism helps lower blood glucose levels in patients with type 2 diabetes by increasing endogenous insulin secretion.","oneSentence":"Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:31:13.822Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07365358","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients","status":"NOT_YET_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2026-03","conditions":"Diabete Type 2","enrollment":200},{"nctId":"NCT00974090","phase":"PHASE3","title":"Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-09","conditions":"Type 2 Diabetes Mellitus","enrollment":194},{"nctId":"NCT06068686","phase":"NA","title":"Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2022-10-01","conditions":"Type 2 Diabetes","enrollment":70},{"nctId":"NCT03118713","phase":"PHASE4","title":"A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria","status":"TERMINATED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2017-04-25","conditions":"Type 2 Diabetes Mellitus","enrollment":33},{"nctId":"NCT00835172","phase":"PHASE1","title":"Glimepiride 4 mg Tablets Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-03","conditions":"Healthy","enrollment":32},{"nctId":"NCT00834340","phase":"PHASE1","title":"Glimepiride 4 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-02","conditions":"Healthy","enrollment":32},{"nctId":"NCT00650533","phase":"PHASE1","title":"Food Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2004-11","conditions":"Healthy","enrollment":40},{"nctId":"NCT00648362","phase":"PHASE1","title":"Fasting Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2004-11","conditions":"Healthy","enrollment":40},{"nctId":"NCT03917940","phase":"NA","title":"Omega 3 Fatty Acids on Serum Irisin and Sirtuin-1 in Type 2 Diabetic Mellitus Patients Treated With Glimepiride","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2019-01-31","conditions":"Diabetic Patients","enrollment":70},{"nctId":"NCT01951339","phase":"NA","title":"Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2013-10","conditions":"Type 2 Diabetes, Cardiovascular Disease","enrollment":36},{"nctId":"NCT03693560","phase":"PHASE4","title":"Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2018-10-08","conditions":"Coronary Artery Disease, Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT04240171","phase":"","title":"Dapagliflozin Versus Glimepiride Effect in Patient With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2020-12-01","conditions":"Diabetes Mellitus, Type 2","enrollment":60},{"nctId":"NCT04183868","phase":"PHASE4","title":"Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)","status":"COMPLETED","sponsor":"University of Catanzaro","startDate":"2016-04","conditions":"Type 2 Diabetes, Cardiovascular Risk Factor","enrollment":26},{"nctId":"NCT05538819","phase":"","title":"The Effects of Glimepiride in Patients With Type 2 Diabetes and Chronic Heart Failure","status":"COMPLETED","sponsor":"Dao Wen Wang","startDate":"2017-06-01","conditions":"Chronic Heart Failure, Type 2 Diabetes, Cardiovascular Mortality","enrollment":1018},{"nctId":"NCT05468879","phase":"NA","title":"Bioequivalence Study of 3 mg Glimepiride Tablet in Indonesia Healthy Subjects","status":"COMPLETED","sponsor":"PT Harsen Laboratories","startDate":"2020-09-21","conditions":"Drug Use","enrollment":34},{"nctId":"NCT00775684","phase":"NA","title":"Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2008-10","conditions":"Pre-diabetes, Type 2 Diabetes","enrollment":47},{"nctId":"NCT04528212","phase":"PHASE4","title":"Fenofibrate Versus Curcumin in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Rehab Werida","startDate":"2020-11-01","conditions":"Diabetes Mellitus, Type 2","enrollment":60},{"nctId":"NCT02338921","phase":"PHASE4","title":"Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-01","conditions":"Type 2 Diabetes","enrollment":78},{"nctId":"NCT02609815","phase":"NA","title":"Initial Combination of Gemigliptin and Metformin on Microbiota Change","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-11-01","conditions":"Diabetes","enrollment":70},{"nctId":"NCT02395237","phase":"PHASE1","title":"COMPOUND (INN): HOE490O - GLIMEPIRIDE / METFORMIN HCl (Amaryl® M)0 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.","status":"WITHDRAWN","sponsor":"Pharmaceutical Research Unit, Jordan","startDate":"2015-05","conditions":"Healthy","enrollment":""},{"nctId":"NCT02964572","phase":"NA","title":"Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-11","conditions":"Type2 Diabetes Mellitus","enrollment":61},{"nctId":"NCT02694263","phase":"PHASE4","title":"Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2016-07","conditions":"Diabetes Mellitus, Type 2","enrollment":25},{"nctId":"NCT02312063","phase":"PHASE4","title":"Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes","status":"COMPLETED","sponsor":"Kansai Electric Power Hospital","startDate":"2015-02","conditions":"Diabetes Mellitus, Type 2","enrollment":48},{"nctId":"NCT02471404","phase":"PHASE4","title":"Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-21","conditions":"Type 2 Diabetes Mellitus, Inadequate Glycaemic Control","enrollment":939},{"nctId":"NCT02728453","phase":"PHASE4","title":"SGLT2 Inhibition and Left Ventricular Mass","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2016-04-27","conditions":"Diabetes Mellitus Type 2","enrollment":7},{"nctId":"NCT02188186","phase":"PHASE4","title":"Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-07","conditions":"Type 2 Diabetes","enrollment":200},{"nctId":"NCT02036515","phase":"PHASE3","title":"Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-12","conditions":"Type 2 Diabetes Mellitus","enrollment":464},{"nctId":"NCT02099110","phase":"PHASE3","title":"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-04-22","conditions":"Type 2 Diabetes Mellitus","enrollment":1233},{"nctId":"NCT01704261","phase":"PHASE3","title":"Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-18","conditions":"Type 2 Diabetes Mellitus","enrollment":307},{"nctId":"NCT01841697","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-06-13","conditions":"Type 2 Diabetes","enrollment":642},{"nctId":"NCT01755156","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-11","conditions":"Type 2 Diabetes Mellitus","enrollment":402},{"nctId":"NCT01863667","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-07-08","conditions":"Type 2 Diabetes Mellitus","enrollment":65},{"nctId":"NCT02033889","phase":"PHASE3","title":"A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-13","conditions":"Type 2 Diabetes Mellitus","enrollment":621},{"nctId":"NCT01682759","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-10","conditions":"Type 2 Diabetes Mellitus","enrollment":751},{"nctId":"NCT01678820","phase":"PHASE3","title":"A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-10","conditions":"Type 2 Diabetes Mellitus","enrollment":299},{"nctId":"NCT00993187","phase":"PHASE4","title":"Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-04","conditions":"Type 2 Diabetes Mellitus","enrollment":292},{"nctId":"NCT01709305","phase":"PHASE4","title":"A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-08","conditions":"Type 2 Diabetes Mellitus","enrollment":5570},{"nctId":"NCT01177384","phase":"PHASE3","title":"Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-25","conditions":"Type 2 Diabetes Mellitus","enrollment":380},{"nctId":"NCT01477853","phase":"PHASE3","title":"A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":166},{"nctId":"NCT02280486","phase":"PHASE4","title":"Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With Metformin","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2015-01","conditions":"Type 2 Diabetes","enrollment":388},{"nctId":"NCT02954822","phase":"PHASE1","title":"Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5mg and Glimepiride 4mg","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2016-11-14","conditions":"Type2 Diabetes","enrollment":36},{"nctId":"NCT02484209","phase":"PHASE3","title":"DiaFrail: A Short Duration Study in Older People ( DIAFRAIL Study)","status":"WITHDRAWN","sponsor":"Diabetes Frail Ltd","startDate":"2016-02","conditions":"Diabetes Mellitus","enrollment":""},{"nctId":"NCT02823808","phase":"PHASE4","title":"Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Function","status":"UNKNOWN","sponsor":"Kyunghee University Medical Center","startDate":"2017-07","conditions":"Diabetes","enrollment":96},{"nctId":"NCT01296412","phase":"PHASE3","title":"Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03-11","conditions":"Diabetes Mellitus, Type 2","enrollment":653},{"nctId":"NCT01189890","phase":"PHASE3","title":"Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-08-16","conditions":"Type 2 Diabetes Mellitus","enrollment":480},{"nctId":"NCT01340768","phase":"PHASE3","title":"Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-22","conditions":"Type 2 Diabetes Mellitus","enrollment":870},{"nctId":"NCT00858013","phase":"PHASE4","title":"Study of the Durability of Glycemic Control With Nateglinide","status":"COMPLETED","sponsor":"Ajou University School of Medicine","startDate":"2009-04-24","conditions":"Type 2 Diabetes Mellitus","enrollment":88},{"nctId":"NCT00032487","phase":"PHASE3","title":"Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2000-12-01","conditions":"Type 2 Diabetes Mellitus","enrollment":1791},{"nctId":"NCT00294723","phase":"PHASE3","title":"To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2006-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":746},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT00842556","phase":"PHASE1","title":"Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-03","conditions":"Type 2 Diabetes Mellitus","enrollment":18},{"nctId":"NCT01829477","phase":"PHASE3","title":"Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"Takeda","startDate":"2013-04","conditions":"Diabetes Mellitus, Type 2","enrollment":33},{"nctId":"NCT02106104","phase":"PHASE4","title":"Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2014-03","conditions":"Type 2 Diabetes","enrollment":48},{"nctId":"NCT00449605","phase":"PHASE3","title":"A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes","status":"TERMINATED","sponsor":"Sanofi","startDate":"2007-03","conditions":"Diabetes Mellitus, Type 2","enrollment":508},{"nctId":"NCT01007097","phase":"PHASE2","title":"Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-12","conditions":"Diabetes Mellitus, Type 2","enrollment":426},{"nctId":"NCT00792935","phase":"PHASE2","title":"A Study to Test MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-0941-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-01","conditions":"Type 2 Diabetes Mellitus","enrollment":143},{"nctId":"NCT00359762","phase":"PHASE3","title":"Exenatide Versus Glimepiride in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Type 2 Diabetes Mellitus","enrollment":1029},{"nctId":"NCT02443922","phase":"NA","title":"Dynamic Responsiveness of Insulin Secretory Parameters To Sitagliptin and Glimeperide Administration in Type 2 DM","status":"UNKNOWN","sponsor":"Foundation for the National Institutes of Health","startDate":"2015-06","conditions":"Type 2 Diabetes","enrollment":100},{"nctId":"NCT02426294","phase":"PHASE4","title":"Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin","status":"UNKNOWN","sponsor":"Pusan National University Hospital","startDate":"2015-02","conditions":"Type 2 Diabetes Mellitus","enrollment":154},{"nctId":"NCT02372955","phase":"PHASE4","title":"Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes","status":"UNKNOWN","sponsor":"Gulf Regional Research & Educational Services, LLC","startDate":"2015-02","conditions":"Diabetes Mellitus Type 2","enrollment":21},{"nctId":"NCT01459809","phase":"PHASE3","title":"Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-02","conditions":"Diabetes Mellitus, Type 2","enrollment":538},{"nctId":"NCT00608179","phase":"NA","title":"Glimepiride Induced Insulin Secretion Will be Inhibited by Hypoglycemia","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2002-08","conditions":"Type 2 Diabetes","enrollment":32},{"nctId":"NCT01099137","phase":"PHASE4","title":"Effect of Vildagliptin in Type 2 Diabetes Treated With Sulphonylurea and Metformin","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2010-01","conditions":"Diabetes","enrollment":344},{"nctId":"NCT01699932","phase":"PHASE3","title":"Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-09","conditions":"Type 2 Diabetes Mellitus","enrollment":167},{"nctId":"NCT01457911","phase":"PHASE3","title":"Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-10","conditions":"Type 2 Diabetes Mellitus","enrollment":244},{"nctId":"NCT01006603","phase":"PHASE4","title":"Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-10","conditions":"Type 2 Diabetes Mellitus","enrollment":957},{"nctId":"NCT00680745","phase":"PHASE3","title":"Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Type 2 Diabetes","enrollment":597},{"nctId":"NCT00506194","phase":"NA","title":"Short-Term Intensive Insulin Therapy Induction of Long-term Glycemic Control","status":"COMPLETED","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2005-10","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT00474838","phase":"PHASE4","title":"Study To Evaluate Beta Cell Function and Glycemic Outcome by Intensive Insulin Therapy","status":"COMPLETED","sponsor":"Kyunghee University Medical Center","startDate":"2007-04","conditions":"Type 2 Diabetes Mellitus, Pancreatic Beta Cell Function, Glucotoxicity","enrollment":112},{"nctId":"NCT01610934","phase":"PHASE2, PHASE3","title":"The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2012-08","conditions":"Maturity-onset Diabetes of the Young","enrollment":15},{"nctId":"NCT00131664","phase":"PHASE3","title":"Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study)","status":"COMPLETED","sponsor":"Canadian Heart Research Centre","startDate":"2005-09","conditions":"Type 2 Diabetes Mellitus","enrollment":391},{"nctId":"NCT00612144","phase":"PHASE4","title":"Study Comparing Efficacy and Safety of Amaryl M and Metformin Uptitraion to Type 2 DM","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2007-12","conditions":"Type 2 Diabetes Mellitus","enrollment":192},{"nctId":"NCT00913367","phase":"PHASE4","title":"Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2009-05","conditions":"Type 2 Diabetes Mellitus","enrollment":110},{"nctId":"NCT00978263","phase":"NA","title":"Comparison of Glargine and Oral Antidiabetic Drugs (OADs) in Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"Chongqing Medical University","startDate":"2009-02","conditions":"Diabetes","enrollment":47},{"nctId":"NCT01660386","phase":"PHASE4","title":"Study of Comparing the Different Effect of DPP-4 Inhibitors and Sulfonylurea by Using \"Biphase-Hyperglycemic Clamp\"","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2012-07","conditions":"Type 2 Diabetes","enrollment":12},{"nctId":"NCT00747383","phase":"NA","title":"How Improvement in Control of Diabetes Influences the Production of a Hormone Produced in the Gut Which Improves the Release and Action of Insulin.","status":"COMPLETED","sponsor":"The Royal Bournemouth Hospital","startDate":"2008-09","conditions":"Type 2 Diabetes Mellitus","enrollment":74},{"nctId":"NCT01496443","phase":"PHASE1","title":"TAK-875 Glimepiride Drug-Interaction Study","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-01","conditions":"Pharmacokinetics","enrollment":28},{"nctId":"NCT01677247","phase":"NA","title":"Bioequivalence Study of 4 mg Glimepiride Tablet","status":"COMPLETED","sponsor":"Dexa Medica Group","startDate":"2011-02","conditions":"Glimepiride BE Study in Healthy Volunteers Under Fasting Condition","enrollment":24},{"nctId":"NCT01444248","phase":"PHASE4","title":"Compare the Compliance of Patients Treated With Once-daily (od) or Twice-daily (Bid) Glimepiride and Metformin Fixed Combination Therapy","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2010-08","conditions":"Type 2 Diabetes Mellitus","enrollment":168},{"nctId":"NCT01318135","phase":"PHASE2, PHASE3","title":"Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-01","conditions":"Type 2 Diabetes Mellitus","enrollment":576},{"nctId":"NCT00908921","phase":"PHASE4","title":"Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono-therapy in Chinese Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-04","conditions":"Diabetes Mellitus, Type 2","enrollment":391},{"nctId":"NCT01624116","phase":"NA","title":"Comparison of Hypoglycaemic Regimens During Ramadan Fasting in Type 2 Diabetes","status":"COMPLETED","sponsor":"Services Hospital, Lahore","startDate":"2011-08","conditions":"Diabetes, Type 2","enrollment":161},{"nctId":"NCT01472497","phase":"PHASE4","title":"Effects of Pioglitazone in Hypertensive Patients","status":"COMPLETED","sponsor":"Tottori University Hospital","startDate":"2007-04","conditions":"Hypertension, Insulin Resistance","enrollment":16},{"nctId":"NCT01204580","phase":"PHASE4","title":"ADIponectin and Asymmetric Dimethylarginine (ADMA) Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose Combination","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-12","conditions":"Diabetes Mellitus, Type 2","enrollment":40},{"nctId":"NCT01453049","phase":"PHASE3","title":"An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat Chinese Type 2 Diabetes Patients","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2010-04","conditions":"Diabetes Mellitus, Type 2","enrollment":86},{"nctId":"NCT00225264","phase":"PHASE3","title":"Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.","status":"COMPLETED","sponsor":"Takeda","startDate":"2003-10","conditions":"Diabetes Mellitus","enrollment":458},{"nctId":"NCT01318083","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-08","conditions":"Type 2 Diabetes Mellitus","enrollment":312},{"nctId":"NCT01509001","phase":"PHASE4","title":"Study of Metabolic and Haemodynamic Effects of Metformin and Glimepiride in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2011-01","conditions":"Type 2 Diabetes","enrollment":20},{"nctId":"NCT01068860","phase":"PHASE2","title":"To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-02","conditions":"Type 2 Diabetes Mellitus, Impaired Glucose Tolerance","enrollment":246},{"nctId":"NCT00924573","phase":"PHASE3","title":"Comparative Study of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-05","conditions":"Type 2 Diabetes Mellitus","enrollment":189},{"nctId":"NCT00151697","phase":"PHASE3","title":"LANN-study: Lantus, Amaryl, Novorapid, Novomix Study","status":"COMPLETED","sponsor":"Rijnstate Hospital","startDate":"2005-05","conditions":"Diabetes Mellitus Type II","enrollment":150},{"nctId":"NCT01144728","phase":"PHASE4","title":"Initiation and Titration of Amaryl","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-05","conditions":"Diabetes Mellitus, Type 2","enrollment":172},{"nctId":"NCT00957060","phase":"PHASE4","title":"Superiority of Glimepiride Over Sitagliptin in Naive Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-07","conditions":"Diabetes Mellitus, Type 2","enrollment":400},{"nctId":"NCT00770653","phase":"PHASE3","title":"Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-04","conditions":"Diabetes Mellitus, Dyslipidemias","enrollment":305},{"nctId":"NCT01053689","phase":"PHASE1","title":"Bioequivalence Study of Dr.Reddys Laboratories Limited, Glimepiride 1 mg Tablets in Healthy Subjects Under Fed Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2003-12","conditions":"Healthy","enrollment":44},{"nctId":"NCT01052909","phase":"PHASE1","title":"Bioequivalence Study of Dr.Reddy's Laboratories Limited, Glimepiride Tablets 1 mg Under Fasting Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2003-12","conditions":"Healthy","enrollment":44},{"nctId":"NCT00934817","phase":"PHASE1","title":"Dose Proportionality Study Comparing Amaryl-M 1/500 mg and Amaryl-M 2/500 mg","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2007-03","conditions":"Healthy","enrollment":36},{"nctId":"NCT00934323","phase":"PHASE1","title":"Dose Proportionality Study About Amaryl M Slow Release (SR) 1/500 mg","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2008-10","conditions":"Healthy","enrollment":33},{"nctId":"NCT00776620","phase":"NA","title":"Bioequivalence Study of Glimepiride 1mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2003-07","conditions":"Healthy","enrollment":32},{"nctId":"NCT00776490","phase":"NA","title":"Bioequivalence Study of Glimepiride 1mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2003-07","conditions":"Healthy","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Glimepiride (HOE490)","genericName":"Glimepiride (HOE490)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}